Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEST CANADA: Naltrexone safety and tolerance
NCT03879460Phase 1Completed
- Start
- Mar 2019
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of naltrexone in opioid intoxication. Primary endpoint: Plasma concentration of naltrexone and its active metabolite, 6 beta naltrexol. Started Mar 2019; status: completed.
02
Drugs
naltrexone
03
Conditions
opioid intoxication
Beyond the preview
Go deeper on NCT03879460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03879460.